11 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly positive
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
, and atezolizumab yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FGEN
3 Jun 24
Tregs via antibody dependent cellular cytotoxicity (ADCC) in the tumor microenvironment and enhance anti-tumor T cell responses, leading to enhanced
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FGEN
3 Jun 24
and explore the potential of FG-3165 in enhancing anti-tumor immune responses in the tumor microenvironment." The FDA IND clearance
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates nearly triple historical results. Should
h4n5casiuwk o42zz7styf21qtpjhl8fh4e
BNTX
CTMX
FGEN
3 Jun 24
that the combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab yielded tumor response rates nearly triple historical results. Should
829w70j8d9wmipggfqqa9kig5n5gqh8tpe9vu4g7zu1lba1q5i47 bnwf
FGEN
23 May 24
of the trial and further explore the potential of 89Zr-DFO-YS5 as a predictive biomarker of response." The poster
rjw2ru9buia9voem1do7d0elronryljld7tnpw8r7hzfe7uvfxs 3bml
FGEN
6 May 24
evaluable patients, 20% met the criteria of a partial response, or measurable tumor reduction in size of ≥ 30%, with a median duration of response
noypu7tq0790 40gctkfc5plimrpms9f5uxyvv5o7hn6hk
ABBV
FGEN
3 Apr 24
evaluable patients.
20% met the criteria of a partial response, or tumor reduction in size of over 30%, with a median duration of response
8uns9elt1 zm8oy
FGEN
2 Apr 24
patients, 20% met the criteria of a partial response, or tumor reduction in size of ≥ 30%, with a median duration of response of 7.5
561q eaicue7xha2u
FGEN
2 Apr 24
PSA50 response in 36% of patients
- Prev
- 1
- Next